SEC Form 4 · accession 0001562180-18-004207
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Olivier Danos
Officer — Chief Scientific Officer
Period of report
Oct 8, 2018
Accepted (ET)
Oct 10, 2018 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 8, 2018 | M | 20,000 | $20.35 | A | 20,000 | D | |
| Common StockF2 | Oct 8, 2018 | S | 3,500 | $62.79 | D | 16,500 | D | |
| Common StockF3 | Oct 8, 2018 | S | 12,284 | $63.73 | D | 4,216 | D | |
| Common StockF4 | Oct 8, 2018 | S | 4,000 | $64.78 | D | 216 | D | |
| Common StockF5 | Oct 8, 2018 | S | 216 | $65.60 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $20.35 | Oct 8, 2018 | M | 20,000 | D | — | Mar 26, 2027 | Common Stock | 20,000 | 80,000 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $62.31 to $63.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $63.35 to $64.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $64.36 to $65.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $65.40 to $65.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.